Guangdong HEC Pharma wins China NMPA approval for insulin degludec injection

PUBT · 2d ago
Guangdong HEC Pharma wins China NMPA approval for insulin degludec injection
  • Guangdong HEC Pharmaceutical won NMPA marketing clearance for insulin degludec injection in China, offered in cartridge and prefilled-pen formats.
  • The approval expands its onshore insulin portfolio to six products, spanning basal, prandial, and premixed therapies.
  • Insulin degludec/insulin aspart is under marketing authorization review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong HEC Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12262734), on July 30, 2026, and is solely responsible for the information contained therein.